1. Guy P. Rising to the productivity challenge. A strategic framework for biopharma. Boston Consulting Group. July 2004

2. Lawyer P, Kirstein A, Yabuki H, Gjaja M, Kush D. High science: a best-practice formula for driving innovation. In Vivo The Business & Medicine Report 2004;22(4):1-12 (BCG authors)

3. Ernst & Young. Resurgence: The Americas perspective. 2004

4. Ernst & Young. Progressions. Global Pharmaceutical Report 2004

5. Lamberti MJ (Ed). An Industry in Evolution, 4th ed. Thomson, CenterWatch. 2003

6. Anonymous. Report to the Nation 2003, Improving Public Health through Human Drugs. Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services.

7. Vander Walde L, Choi K, Higgins J. Health Care Industry Market Update. Pharmaceuticals. Centers for Medicare and Medicaid Services. Department of Health and Human Services. January 2003, 1-52

8. Anonymous. Health Care in America. Trends in Utilization. Centers for Disease Control. Department of Health Human Services. 2002, 1-90

9. Lahteenmaki R, Baker M. Public biotechnology 2003—the numbers. Nature Biotechnology 2004;22(6):665-670

10. Booth B, Zemmell R. Prospects for productivity. Nature Reviews Drug Discovery 2004;3(5):451-456

11. Rawlins MD. Cutting the cost of drug development. Nature Reviews Drug Discovery 2004;3(4):360-364

12. 15th annual report top 50 pharmaceutical companies. Med Ad News 2003;22(9):4-19

13. Sellers LJ (ed). Our 5th annual report of the world's top 50 pharma companies. Pharmaceutical Executive 2004;24(5):60-70

14. Trombetta B. Industry audit & "fab four' companies of the year. Pharmaceutical Executive 2003;23(9):38-64

15. From pipeline to market 2004. Areas of interest. R&D Directions 2004;10(6):8-18

16. King J. Advances in medicine.100 great investigational drugs. R&D Directions 2004;10(3):31-51

17. Engel S. How to manage a winning pipeline. R&D Directions 2002;(2):36-41

18. Anonymous. Profile pharmaceutical industry 2004, Focus on innovation. PhRMA, 2004.

19. Anonymous. PhRMA. Industry profile 2003. Prescription medicines 25 years ago and today: changing trends, enduring needs. 1-81

20. Ernst & Young. The economic contributions of the biotechnology industry to the US economy. May 2000, Biotechnology Industry Organization

21. Tufts Center for Study of Drug Development. Outlook 2005;1-5

22. Tufts CSDD. Outlook 2004;1-8

23. Tufts CSDD. Outlook 2003;1-8

24. Tufts CSDD. Outlook 2002;1-5

25. Tufts CSDD. Outlook 2001;1-5

26. Matthieu M (ed.). Parexel's Pharmaceutical R&D Statistical Sourcebook 2005-2006. Parexel Publishing, Boston, MA. 2005

27. Anonymous. Health, United States, 2004. National Center for Health Statistics. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.

28. Edwards MG, Murray F. Yu R. Value creation and sharing among universities, biotechnology and pharma. Nature Biotechnology 2003;21(6):618-624

29. Resnick JT. Reputation the inside story. Pharmaceutical Executive 2003;23(6):40-48

30. Gasorek DW, Resnick JT. The rise and fall of pharma reputations. Pharmaceutical Executive 2005;25(2):76-83

31. Maggon K. The ten billion dollar molecule. Pharmaceutical Executive 2003;23(11):60-68

32. Bogan C, Wang D. Launching a blockbuster. Pharmaceutical Executive 2000;20(8):96-104

33. Booth B, Zemmel R. Quest for the best. Nature Reviews Drug Discovery 2003;2(10):838-841

34. King J. Today's drug discovery unlocking greater potential. R&D Directions 2004;10(2):28-39

35. Lindsay MA. Target discovery. Nature Reviews Drug Discovery 2003;2(10):831-837

36. Lombardino JG, Lowe III JA. The role of the medicinal chemist in drug discovery—then and now. Nature Reviews Drug Discovery 2004;3(10):853-862

37. Product failures

38. Garaud J-J. The most diversified development pipeline, innovation, focus, productivity. R&D Directions 2004 Drug Development Summit, How to Build and Maintain a Winning Pipeline. Feb. 8-11, 2004.

39. Bellucci NM. The top 10 pipelines. Novartis: most productive and strongest primary care pipeline. Stroing and steady. R&D Directions 2005;11(1):50-53

40. Amgen Web site (, December 2004.

41. Bellucci NM. Top 10 pipelines. Amgen: most advanced pipeline/best biotechnology pipeline. R&D Directions 2005;11(1):32-35

42. Bellucci NM. Top 10 pipelines. R&D Directions 2005;11(1): 32-66.

43. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery 2004;3(8):673-683

44. Frei P, Leleux B. Valuation—what you need to know. Nature Biotechnology 2004;22(8):1049-1051

45. Tollman P, Goodall S, Ringel M. The gentle art of licensing. Rising to the productivity challenge in biopharma R&D. Boston Consulting Group. July 2004

46. Arnold K, Coia A, Saywell S, Smith T, Minick S, Loffler A. Value drivers in licensing deals. Nature Biotechnology 2002;20(11):1085-1089

47. Featherstone J, Renfrey S. From the analyst's couch. The licensing gamble: raising the stakes. Nature Reviews Drug Discovery 2004;3(2):107-108

48. Webber PM. Protecting your inventions: the patent system. Nature Reviews Drug Discovery 2003;2(10):823-830

49. Rubinger B, Davis H. Protecting IP throughout the product life-cycle. Pharmaceutical Executive 2003;23(8):40-48

50. Steffe EK, Shea Jr TJ. Protecting innovation in biotechnology startups. Nature Biotechnology Supplement 21:BE51-BE53, 2003

51. Lam LD. Biotech+Pharma dangerous liaisons. Pharmaceutical Executive 2004;24(5):72-80

52. Engel S. Drug-discovery companies aim for commercialization. Good leads good medicine. R&D Directions 2002;8(7):34-42

53. Lam MD. Biotech+pharma. Why alliances fail. Pharmaceutical Executive 2004;24(6):56-66

54. Ansell J. The billion dollar pyramid. Megamergers' greatest challenge. Pharmaceutical Executive 2000;(8):64-72

55. Bogan C, Symmers K. Marriages made in heaven. Pharmaceutical Executive 2001;(1):52-60

Was this article helpful?

0 0
Outsourcing Survival Kit

Outsourcing Survival Kit

Tired Of Being Tied Down By Time? Wish You Could Achieve More And Earn More Within The Deadlines You Are Given? Want To Branch Out To Other Lucrative Areas Without Sacrificing Your Current Business?

Get My Free Ebook

Post a comment